bovnews15h
Quoin Pharmaceuticals Ltd – ADR (QNRX) Stock: More Strategic Than Meets the Eye
ADR (QNRX) stock price has shown some volatility, fluctuating -40.30% over the last five trades and -34.67% over the past 30 trades. This represents a notable shift from earlier in the year. Over the ...
bovnews3d
Quoin Pharmaceuticals Ltd – ADR (QNRX) Stock: More Resilient Than It Appears
ADR (QNRX) stock price has shown some volatility, fluctuating -35.40% over the last five trades and -33.06% over the past 30 trades. This represents a notable shift from earlier in the year. Over the ...
12 Health Care Stocks Moving In Friday's Pre-Market Session
Evaxion Biotech EVAX stock increased by 87.1% to $6.81 during Friday's pre-market session. The market value of their outstanding shares is at $39.9 million. Aclarion ACON stock moved upwards by 63.19% ...
Quoin Pharmaceuticals: Buy Rating Affirmed Amidst Potential First-Mover Advantage in Netherton Syndrome Treatment
Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Quoin Pharmaceuticals (QNRX – Research Report) and keeping the price target at ...
Quoin Pharmaceuticals reports setback in Netherton Syndrome study
The information for this report is sourced from a press release statement filed by Quoin Pharmaceuticals with the SEC. The stock currently trades at $0.41, near its 52-week low of $0.42, reflecting ...
QNRX Stock Hits 52-Week Low at $0.42 Amid Market Challenges
In a turbulent market environment, QNRX stock has reached a new 52-week low, trading at just $0.42. According to InvestingPro data, while the company maintains a FAIR financial health score and holds ...
Quoin Pharmaceuticals announces further clinical evidence on QRX003 efficacy
Quoin Pharmaceuticals (QNRX) announces further clinical evidence of the potential efficacy of QRX003 in Netherton Syndrome. In December 2024 ...
Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome
After Discontinuation of Treatment with QRX003 Complete Reversal of Positive Clinical Improvements Across all Measured ...
Skinvisible, Inc.: Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
LAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and ...
BioSpace14d
Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study
Jan. 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today ...
Investing14d
Quoin reports progress in pediatric skin disorder study
ASHBURN, Va. - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company with a market capitalization of $2.89 million, announced positive interim clinical data from ...